Background and Current Status of FDA Regulatory Database Update

The FDA regulatory information for Kenvue's (Kenvue, KVUE) leading OTC allergy medication, Zyrtec-D 12 Hour, has been updated. This product is a bilayer extended-release tablet containing two active ingredients: cetirizine hydrochloride (5mg) and pseudoephedrine hydrochloride (120mg). Initially approved as a prescription drug (Rx) in August 2001, it subsequently received approval for over-the-counter (OTC) status in November 2007 (NDA 021150/S-007), establishing it as a key product in the U.S. consumer market. This information update is part of Kenvue's regular data maintenance efforts to demonstrate the company's independent regulatory approval management capabilities and ensure the longevity and regulatory compliance of its product portfolio, following its spin-off from Johnson & Johnson (J&J).

Dual Mechanism of Action and Clinical Significance

Zyrtec-D 12 Hour provides comprehensive symptom relief through the combination of an antihistamine and a nasal decongestant. Cetirizine, a second-generation antihistamine, selectively blocks histamine H1 receptors triggered by allergens, thereby suppressing sneezing, runny nose, and itching. Simultaneously, pseudoephedrine, an alpha-adrenergic receptor agonist, constricts blood vessels in the nasal passages, rapidly relieving nasal congestion and sinus pressure. This dual mechanism provides immediate and sustained relief for patients with severe nasal congestion, which cannot be adequately addressed by single-ingredient antihistamines, significantly improving their quality of life.

Global Allergy Market Landscape and Competitive Dynamics

The global allergy treatment market is estimated at approximately USD 25 billion by 2026 and is growing at a steady rate of about 5% annually. Kenvue's Zyrtec brand competes fiercely with Sanofi's (Sanofi, SNY) Allegra-D and Bayer's (Bayer, BAYN) Claritin-D for market share in the OTC market. The market for combination products containing pseudoephedrine is subject to strict distribution regulations, as it is sold only behind the pharmacy counter due to the Combat Methamphetamine Epidemic Act (CMEA), a U.S. federal law aimed at preventing the illegal manufacture of drugs. Kenvue continues to maintain sophisticated supply chain and regulatory management to ensure brand trust and accessibility in this complex regulatory environment.

Kenvue's Strategy to Strengthen its Independent Portfolio

Since its successful separation from Johnson & Johnson, Kenvue has demonstrated its ability to generate independent growth, with annual net sales of approximately USD 15 billion. Maintaining key assets such as Zyrtec-D 12 Hour is essential for demonstrating the company's regulatory capabilities to the market and protecting its brand value. With the allergy season in North America becoming longer and more variable due to climate change, it is even more important to defend sales in the consumer healthcare sector. Kenvue is strengthening its independent OTC market leadership by pursuing diversification of marketing channels and optimization of the supply chain, based on its solid regulatory reliability.